Literature DB >> 30449018

Clinical presentation of 54 patients with endogenous hyperinsulinaemic hypoglycaemia: a neurological chameleon (observational study).

Luca G Valente1, Kwadwo Antwi2, Guillaume P Nicolas2, Damian Wild2, Emanuel Christ3.   

Abstract

BACKGROUND Important causes of endogenous hyperinsulinaemic hypoglycaemia (EHH) in adult patients are insulinoma and adult nesidioblastosis. Data on main symptoms in EHH are scarce and controversial. We analysed main symptoms of patients with EHH in the framework of two prospective studies investigating glucagon-like peptide-1 receptor imaging. METHODS Patients were referred from secondary European endocrine centres and endocrinologists. Inclusion criteria were biochemically proven EHH (glucose <2.5 mmol/l in the presence of inadequate insulin and C-peptide levels) with neurological hypoglycaemic symptoms. Demographic characteristics and aetiologies of the patients with EHH were retrieved. Main symptoms were categorised into neurological, sympathicoadrenal (sweating, tremor, palpitation, hunger, shivering and pallor) and nonspecific other symptoms (nonspecific asthenia, weight gain, gastrointestinal symptoms and headaches). Neurological symptoms were subdivided into moderately impaired consciousness (confusion, dizziness, somnolence and delirium), visual, speech and sensorimotor impairment, severely impaired consciousness (loss of consciousness and apathy), attention deficit, seizures and personality changes. Biochemical assessment and duration of EHH at the end of a fasting test were recorded. RESULTS Fifty-four patients with full documentation were included in the analysis (74% female; mean age 54 years, range 22–84). Median duration from onset of symptoms to diagnosis of EHH was 12 months (range 0–120). Fifty (92.6%) patients had neurological symptoms, including moderately impaired consciousness (46.3%), visual, speech and sensorimotor function impairment (44.4%), severely impaired consciousness (37%), attention deficit (31.5%), seizures (16.7%) and personality change (13%). Sympathicoadrenal symptoms were present in 33 (61.1%) patients. Nonspecific other symptoms occurred in 36 (66.7%) patients. 43 patients (79.6%) suffered from symptoms of at least two different categories. CONCLUSIONS Clinical symptoms of EHH are characterised by a wide variety of mainly different neurological symptoms (“neurological chameleon”). EHH should be considered as a differential diagnosis in many neurological disorders. Trial registration numbers NCT00937079 & NCT02127541

Entities:  

Keywords:  endogenous hyperinsulinaemic hypoglycaemia; insulinoma; adult nesidioblastosis; main symptoms

Mesh:

Substances:

Year:  2018        PMID: 30449018     DOI: 10.4414/smw.2018.14682

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  7 in total

1.  Insulinoma-Accurate Preoperative Localization Is the Key to Management: An Initial Experience.

Authors:  Ajay Sharma; Peeyush Varshney; Rajeev Kasliwal; Anand Nagar; Krishnavardhan Venkatatelikicherla; Shashwat Sarin; R P Choubey; V K Kapoor
Journal:  Indian J Surg Oncol       Date:  2022-04-26

2.  Commentary: Insulinoma-Induced Hypoglycemia with Generalized Chorea, Dystonia, and Ataxia: A Neurological Kaleidoscope.

Authors:  Maria Stamelou; Anumeha Mishra; Sonali Bhattad; Sanjay Pandey; Victor S C Fung
Journal:  Mov Disord Clin Pract       Date:  2021-09-03

Review 3.  Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management.

Authors:  Francesca Spada; Roberta E Rossi; Elda Kara; Alice Laffi; Sara Massironi; Manila Rubino; Franco Grimaldi; Sherrie Bhoori; Nicola Fazio
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-04

4.  Insulinoma presenting as hypoglycemia during lactose tolerance testing: a case report.

Authors:  Vicki Munro; Laura M McDonell; Valerie Keough; Ferhan S Siddiqi
Journal:  J Med Case Rep       Date:  2020-06-30

Review 5.  Exendin-4 analogs in insulinoma theranostics.

Authors:  Tom J P Jansen; Sanne A M van Lith; Marti Boss; Maarten Brom; Lieke Joosten; Martin Béhé; Mijke Buitinga; Martin Gotthardt
Journal:  J Labelled Comp Radiopharm       Date:  2019-08       Impact factor: 1.921

6.  Radiofrequency Ablation as a Primary Therapy for Benign Functioning Insulinoma.

Authors:  Ebtihal Y Alyusuf; Aishah A Ekhzaimy; Juan A Rivera
Journal:  AACE Clin Case Rep       Date:  2020-12-28

Review 7.  Innovative imaging of insulinoma: the end of sampling? A review.

Authors:  Emanuel Christ; Kwadwo Antwi; Melpomeni Fani; Damian Wild
Journal:  Endocr Relat Cancer       Date:  2020-04       Impact factor: 5.678

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.